Genocea Biosciences Inc RSI
What is the RSI of Genocea Biosciences Inc?
The RSI of Genocea Biosciences Inc is 21.09
What is the definition of RSI?
The relative strength index (RSI 14) is a momentum indicator that compares the magnitude of gains and losses over a specified time period to measure speed and change of price movements of a security.
14-day period
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI of companies in the Health Care sector on NASDAQ compared to Genocea Biosciences Inc
What does Genocea Biosciences Inc do?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Companies with rsi similar to Genocea Biosciences Inc
- Akazoo S.A has RSI of 21.04
- Delfingen Industry SA has RSI of 21.04
- Holiday Island has RSI of 21.05
- Oriental Press has RSI of 21.07
- Elanor Retail Property Fund has RSI of 21.07
- Qantm Intellectual Property has RSI of 21.08
- Genocea Biosciences Inc has RSI of 21.09
- Longfor Properties Co has RSI of 21.12
- Ssif ETF I - Ssif Dce Iron Ore Futures Index ETF has RSI of 21.12
- Rare Earth Magnesium Technology has RSI of 21.13
- Arcimoto has RSI of 21.16
- VBI Vaccines has RSI of 21.17
- Future Supply Chain Solutions has RSI of 21.18